DOSE-RANGING PAEDIATRIC STUDY: IDENTIFICATION OF A NOVEL MF59-ADJUVANTED 2A2B QUADRIVALENT INFLUENZA VACCINE
ESPID Education. Vesikari T. Jun 7, 2011; 7747
Prof. Timo Vesikari
Prof. Timo Vesikari

This content is available to ESPID members only


Click here for more information or if you are considering becoming an ESPID member.

Abstract
Discussion Forum (0)
Rate & Comment (0)
Timo Vesikari
Tampere, Finland
Professor Timo Vesikari is Professor of Virology and Pediatrics and Director of the Vaccine Research Centre, University of Tampere, Finland. Professor Vesikari obtained his MD at the University of Helsinki in 1969 and Ph.D. in 1972. He was appointed Acting Professor of Pediatrics at the University of Tampere in 1981, where he carried out the first clinical trials of rotavirus vaccines. Between 1987 and 1990 he was responsible for research on diarrhoeal vaccines as part of the Diarrhoeal Control Programme at the WHO. Professor Vesikari is well respected expert in the field of pediatric infectious diseases; he has previously acted as chairman for the Finnish Society for the Study of Infection, in 1990 he gave the ESPID Bill Marshall lecture, in 2007 he was awarded a joint Outstanding Achievement Award with Professor Guillermo M Ruiz-Palacios for their work on rotavirus vaccination; the respective publications in 2006 were also elected as “Papers of the Year” by The Lancet in 2007. Professor Vesikari has published extensively; he is co-author on numerous clinical studies on pediatric vaccines and has been invited to present his work at international meetings
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings